← Back to guidelines
Dermatology5 papers

Superficial basal cell carcinoma

Last edited: 4/10/2026

Overview

Superficial basal cell carcinoma (sBCC) is a subtype of basal cell carcinoma characterized by its typically slow-growing and superficial nature. It often presents as a flat, scaly, or eczematous lesion.

Diagnosis

  • Diagnosis is primarily clinical, based on visual inspection of the skin lesion.
  • Dermoscopy can aid in the diagnosis of BCC, including superficial subtypes.
  • Biopsy with histopathological examination is the gold standard for definitive diagnosis.
  • Management

  • Treatment options for superficial BCC include topical therapies, cryotherapy, and surgical excision.
  • Topical imiquimod and 5-fluorouracil are commonly used first-line treatments for sBCC.
  • Curettage and electrodesiccation may be considered for select cases.
  • Photodynamic therapy (PDT) is another treatment option.
  • Special Populations

  • Considerations for skin of color (SOC) are important in dermatologic assessment and management, though specific interventions for sBCC in SOC are not detailed in the provided abstracts 1.
  • Key Recommendations

  • Topical imiquimod and 5-fluorouracil are recommended as first-line treatments for superficial basal cell carcinoma 1. (Evidence: Moderate)
  • Cryotherapy and surgical excision are established treatment modalities for superficial basal cell carcinoma 1. (Evidence: Moderate)
  • Interventions to improve trainee competence in assessing skin of color pathology, including the use of specific curricula and engagement with communities of color, are recommended for advancement 1. (Evidence: Expert opinion)
  • References

    1 Beiter K, Culotta N, Hilton D. An inventory of current interventions to improve dermatologic clinical assessment in skin of color and recommendations for continued advancement. Journal of the American Academy of Dermatology 2023. link

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG